Exclusive Content

DDW’s Megan Thomas looks at a day in the life of Giusy Di Conza, Head of Research at iOnctura. MT: Where do you work, and can you tell us what you’re working on at the moment? GDC: I’m Head of Research for a young, dynamic biotech called iOnctura. We are pioneering research into new biological […]

In the second part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates the use of psilocybin in drug discovery. The first part explored medical cannabis.  What is the regulatory landscape of psilocybin?  Psilocybin is a naturally occurring psychedelic compound that is produced by more than 200 species of fungi. Despite […]

Asks Matt Clifford, Director, Research and Innovation Strategy, IDBS. When it comes to technology transformations, sometimes finding the right solution comes from asking the wrong question. One ‘wrong question’ that I hear a lot is: “Is it time for our lab to invest in a new electronic lab notebook (ELN)?” In many labs, a standard […]

Claire D’Abreu-Hayling, Chief Scientific Officer at Sandoz, examines how generic products can relieve industry pressure and improve access to essential medicines.   Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost. This will continue to be the case going forward, but the nature of the off-patent landscape will […]

Diana Spencer investigates therapies in clinical development for triple-negative breast cancer and asks what future treatments might look like. Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases and is one of the main causes of death in women. However, because these cancers are not driven by any of the three […]

DDW’s Diana Spencer speaks to Alok Javali, CSO of dawn-bio, a new addition to BioInnovation Institute’s (BII) Venture Lab acceleration programme, about the lack of innovation in women’s reproductive health and the company’s plans to fill the vacuum. Earlier this year, dawn-bio was one of five drug discovery companies to enter the BioInnovation Institute’s (BII) […]

Samir Ounzain, PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines. Over the next two decades, it is quite possible that most […]

Can potentially lethal arrhythmias induced by novel drugs be better predicted by using more relevant and sophisticated electrophysiological screening methods? By Dr J Mark Treherne, Dr W Jack Scannell and Dr Richard C Saumarez. Single-cell, electrophysiology-based screening systems are now routinely incorporated as pivotal decision-making assays, early into the drug discovery process to assess cardiovascular safety. […]

This paid-for advertorial by Taconic appeared in DDW Volume 24 – Issue 3, Summer 2023 Overcoming challenges in model generation Genetically engineered mouse models are essential tools for biomedical research. Yet when seeking to obtain an existing model, researchers often encounter obstacles related to intellectual property, availability, or licensing. As a result, model generation is an […]

Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at AmerisourceBergen, and Cori Gorman, Senior Director of CMC and Regulatory Affairs at Biopharma Excellence, offer advice on navigating the different and sometimes contradictory regulatory requirements in the US and EU. Over the past few decades, the incredible progress in personalised medicine […]

In this article, Amplexor asks some of the company’s closest industry partners and BE THE EXPERT event speakers for their views on the biggest developments in the Life Sciences Regulatory sphere over the last 12 months – and explore some of the most prominent themes and priorities seen throughout 2023.   Those asked to share their […]

In Nicotine dependence and smoking cessation, a paper available in the National Library of Medicine, co-authors shared that tobacco use is the single most preventable cause of death, disability and disease in the world and was projected to be the leading cause of death and disability across all developed and developing countries by 20201. In […]

Reece Armstrong speaks to Neil Dhawan, the Co-founder and CEO of Totus Medicines about the company’s approach to drug discovery using fundamental technologies in chemistry, biology and artificial intelligence (AI). RA: How is Totus Medicines attempting to target untreatable or undruggable diseases? ND: Discovering a highly effective drug is like winning the lottery. If you […]

AstraZeneca UK has appointed David Brocklehurst as Head of Oncology in the UK. He spoke with DDW’s Megan Thomas about how AstraZeneca is innovating to displace chemotherapy and research areas of significance. MT: What will you be focusing on in your new role? DB: We have three priorities as an oncology business: supporting earlier diagnosis […]

DDW’s Megan Thomas takes a deeper look into why India is ramping up drug discovery research, and explores the country’s innovation hubs of interest. In the global pharmaceuticals market, India ranks third worldwide for production by volume and the domestic pharmaceutical market is expected to reach US$120-130 billion by 20301. According to a report by […]

DDW’s Reece Armstrong speaks to Shantanu Dhamija, VP of Strategy and Innovation at Molecular Devices about challenges of diversity in clinical trials and why induced pluripotent stem cells might be key to representing wider patient groups.   RA: Why is US clinical trial diversity at its lowest point in the last 10 years?   SD: The […]